SCHEMBL10036372

SCHEMBL10036372

O=[N+]([O-])c1ccc(C2=CCNCC2)c(F)c1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 6/20 0.53
HTR2A P28223 1/20 0.53
ADRA2A P08913 1/20 0.44
PNMT P11086 1/20 0.44
KHK P50053 1/20 0.41
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 1/20 0.41
HTR2C P28335 4/20 0.41
HIF1A Q16665 1/20 0.41
ALOX5AP P20292 1/20 0.40
FEN1 P39748 1/20 0.40
CYP3A4 P08684 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SIGMAR1 Q99720 1/20 0.38
PTPRC P08575 1/20 0.38
S100A4 P26447 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31333875 1.00 HTR6 (0.53) HTR6HTR2AADRA2APNMTKHK
SCHEMBL6410070 0.89 HTR6 (0.53) HTR6HTR2AADRA2APNMTKHK
Hydrochloric Acid SCHEMBL17630885 0.83 HTR6 (0.59) HTR6HTR2AADRA2APNMTKHK
SCHEMBL520900 0.83 HTR6 (0.59) HTR6HTR2AADRA2APNMTKHK
SCHEMBL519626 0.83 HTR6 (0.50) HTR6HTR2AADRA2APNMTKHK
SCHEMBL519662 0.80 HTR6 (0.53) HTR6HTR2AADRA2APNMTKHK
Hydrochloric Acid SCHEMBL9958496 0.79 HTR2C (0.57) HTR6HTR2AADRA2APNMTKHK
SCHEMBL26130709 0.78 ALDH1A1 (0.47) ALDH1A1KMT2AHIF1ACYP3A4TDP1
SCHEMBL4775022 0.77 HTR6 (0.53) HTR6HTR2AADRA2APNMTKHK
Hydrochloric Acid SCHEMBL29882492 0.77 HTR6 (0.50) HTR6HTR2AHTR2CSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709720-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2026-03-18 EP disclosed
WO-2024233846-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN LARKSPUR BIOSCIENCES, INC. (US) 2024-11-14 WO disclosed
CN-118084916-A Tri-heterocyclic compounds and uses thereof 成都赜灵生物医药科技有限公司 2024-05-28 CN disclosed
CN-117940133-A Therapeutic agents for degradation of mutant BRAF C4医药公司 2024-04-26 CN disclosed
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2023-10-19 US disclosed
WO-2012053606-A1 ARYLAMINOHETEROCYCLIC CARBOXAMIDE COMPOUND アステラス製薬株式会社 (JP) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN HTR6 707/4885HTR2A 1200/4885ADRA2A 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.